<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116675</url>
  </required_header>
  <id_info>
    <org_study_id>1535-RESI</org_study_id>
    <nct_id>NCT00116675</nct_id>
  </id_info>
  <brief_title>Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects</brief_title>
  <official_title>A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graceway Pharmaceuticals, LLC</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of&#xD;
      three different strengths of resiquimod gel applied to common wart(s) three times a week for&#xD;
      four weeks.&#xD;
&#xD;
      A second purpose is to evaluate the safety of the drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of treated wart(s)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial clearance of treated wart(s)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wart recurrence</measure>
  </secondary_outcome>
  <enrollment>84</enrollment>
  <condition>Warts</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiquimod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of common warts&#xD;
&#xD;
          -  Ages between 3 to 11&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other types of wart(s), ie. plantar&#xD;
&#xD;
          -  Currently participating in another clinical study&#xD;
&#xD;
          -  Chronic viral hepatitis B or C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Clinic of Jonesboro, PA</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Clinic/Longmont Medical Research Network</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital - Jane Brown Building</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Pediatrics</name>
      <address>
        <city>Pleasant Grove</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walla Walla Clinic</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Healthcare</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2005</study_first_posted>
  <last_update_submitted>February 16, 2007</last_update_submitted>
  <last_update_submitted_qc>February 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2007</last_update_posted>
  <keyword>Common Wart(s)</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Wart(s)</keyword>
  <keyword>Children</keyword>
  <keyword>3M Pharmaceuticals</keyword>
  <keyword>Resiquimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

